AstraZeneca Strikes Covid-19 Deal With U.S Defense, Medical Agencies

The transcript discusses AstraZeneca's collaboration with US agencies and Vanderbilt University to develop antibodies for COVID-19. It explains the concept of passive vaccines and their role in providing temporary immunity. The conversation also touches on the political implications of AstraZeneca's involvement in the US market. Additionally, it highlights the competitive landscape of companies like Eli Lilly and Regeneron in the antibody development race. The transcript concludes with an update on the progress of COVID-19 treatments and vaccines, emphasizing the importance of upcoming human trial data.

What role does Eli Lilly play in the development of antibody treatments?

What are the expectations for data release from Moderna and other companies in June and July?